Professor of Cardiology
European Hospital Georges Pompidou, Paris, France
Paris, France
Christian Spaulding, MD, PhD is professor of cardiology at Paris Descartes University, Paris, France. He is head of the interventional cardiology department at the European Hospital Georges Pompidou since January 2012, and head of the multi-disciplinary interventional department since October 2016. His main research topics are out of hospital cardiac arrest, coronary stents, drug coated balloons and techniques in percutaneous coronary intervention. He has published over 240 manuscripts in peer reviewed journals, including landmark studies on the value of coronary angiography and angioplasty in out-of-hospital cardiac arrest, long term outcome of drug eluting stents, and drug coated balloons
Disclosure(s): Abbott, Asahi, BD, Boston Scientific, Conavi, Cook, Cordis, Endovascular Engineering, Evident Vascular, Gore, InfraRedx, Medtronic, Penumbra, Philips, RapidAI, Rampart IC, R3, Regeneron, Shockwave, Siemens, SoniVie, Teleflex, Terumo, Thrombolex, Vent: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scietific: Consulting Fees (e.g., advisory boards) (Terminated, September 30, 2025); CERC: Grant/Research Support (Ongoing); Cordis, Endovascular Division: Consulting Fees (e.g., advisory boards) (Ongoing); Daiichi Sankyo, Boeringer Ingelheim , Sanofi, AstraZeneca , Chiesi, Bracco, Amgen, Novo Nordisk, Philips: Consulting Fees (e.g., advisory boards) (Terminated, June 30, 2025); French Ministry of Health: Grant/Research Support (Terminated, January 2, 2025); MedAlliance: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Terminated, July 30, 2025); Techwald: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Valcare Medical: Consulting Fees (e.g., advisory boards) (Terminated, September 30, 2025)